Nintedanib Ratiopharm

Nintedanib, the active ingredient in Nintedanib Ratiopharm, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib is an antifibrotic and antineoplastic agent that targets multiple tyrosine‑kinase pathways involved in fibrosis and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and delays worsening of lung fibrosis. - Non‑small cell lung cancer (in combination therapy): enhances efficacy of chemotherapy regimens and may improve progression‑free survival.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhoea: frequent loose stools, often manageable with hydration. - Abdominal pain: cramping or discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Vomiting: occasional episodes of expulsion of stomach contents.

Serious or Rare Side Effects: - Elevated liver enzymes: potential indication of hepatic injury. - Arterial thromboembolic events: risk of blood clots in arteries. - Severe bleeding: increased susceptibility to gastrointestinal or other bleeding. - Gastrointestinal perforation: rare but serious tearing of the GI tract.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: assess baseline and monitor during treatment. - Hepatic function: avoid in patients with severe hepatic impairment; monitor liver enzymes regularly. - Bleeding risk: use caution in patients receiving anticoagulants or antiplatelet agents. - Pregnancy and lactation: safety not established; avoid use in pregnant or nursing women. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Nintedanib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase risk of serious bleeding. - Concurrent VEGF inhibitors: additive toxicity, especially hypertension and proteinuria.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise nintedanib plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can increase systemic exposure. - Diuretics: may exacerbate dehydration from gastrointestinal losses, requiring fluid monitoring.